Table 1:

Cytokine release syndrome, neurotoxicity and response rates in selected CD19 CAR-T cell trials.

Cell product	Malignancy	Study	Population	Costim-ulatory Domain	Lymphodepletion	Cell dose	CRS grading system	CRS Total/ severea	NT grading system	NT Total/ severeb	Best ORR/CR
Tisagenlecleucel	ALL	Maude, et al [6]	75 pediatric/ young adult patients	4-1BB	Flu/Cy in 71 patients and cytarabine/etoposide in 1 patientc	0.2–5.4 x 106/kg	PENN grading [26]	77%/47%	CTCAE 4.03[47]	40%/13%	N/A/81% d
Tisagenlecleucel	NHL	Schuster, et al [7]	111 adult patients	4-1BB	Flu 25mg/m2/day and Cy 250mg/m2/day x 3 days or Bendamustine 90mg/m2/day x 2 days	0.1–6 x 108	PENN grading	58%/22%	CTCAE 4.03	21%/12%	52%e/40%
Axicabtagene ciloleucel	NHL	Neelapu, et al [2]	101 adult patients	CD28	Flu 30mg/m2/day and Cy 500mg/m2/day x 3 days	2 x 106/kg	Lee, et al [25]	93%/13%	CTCAE 4.03	64%/28%	82%f/54%
Lisocabtagene maraleucel	NHL	Abramson, et al [48,61]	91 adult patients	4-1BB	Flu 30mg/m2/day and Cy 300mg/m2/day x 3 days	0.5–1 x 108 (1:1 ratio of CD4:CD8 CAR-T cells)	Lee, et al	35%/1%	CTCAE 4.03	19%/12%	74%e/52%

ALL - acute lymphoblastic leukemia

CRS - cytokine release syndrome

CTCAE - Common Terminology Criteria for Adverse Events

CR - complete response

Cy - cyclophosphamide

Flu - fludarabine

NT - neurotoxicity

ORR - overall response rate

NHL - non-Hodgkin's lymphoma

^asevere is grade 3 or higher, grading systems differ

^bCTCAE 4.03 grading criteria, severe is grade 3 or higher [47]

^cdoses and duration not specified

^dminimal residual disease negative by flow cytometry with and without complete hematologic recovery

^eLugano classification [59]

^fInternational Working Group Response Criteria for Malignant Lymphoma [60]